NCT05627245 2026-04-22Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted TreatmentNational Cancer Institute (NCI)Phase 1 Active not recruiting48 enrolled
NCT02978625 2026-04-13Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersNational Cancer Institute (NCI)Phase 2 Active not recruiting68 enrolled
NCT03017820 2026-04-13A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaMayo ClinicPhase 1 Recruiting127 enrolled
NCT06712810 2025-10-10Q702 for the Treatment of Patients With Hematologic MalignanciesMayo ClinicPhase 1 Recruiting46 enrolled